Healthcare Technology Disruptor Obtains National Reach

74
Google Ads

If you haven’t heard the name Healixa by now, you will in the near future.  

With its combination of healthtech and fintech assets, Healixa has been able to develop a uniquely seamless virtual care ecosystem which ties a telehealth platform with a broad range of specialties and expanding scope of practice to digital pharmacy capabilities offering same-day delivery to the door.

Healixa, Inc. (OTC Pink: EMOR), just yesterday announced a new global rideshare relationship that will enable “last-mile” delivery services of prescriptions directly to the customers’ doorsteps nationwide.

By launching with a global rideshare operation, Healixa expedites its ability to service customers in almost any large metropolitan area and quickly penetrate those markets.

Ian Parker, CEO of Healixa, Inc. commented, “In the last several weeks, we have been asked repeatedly how Healixa will be able to logistically deliver patient scripts throughout the country. Launching with an established rideshare network solves that part of the puzzle and gives us the ability to go national (or even global) rapidly. 

The “Last Mile” solution has been highly anticipated.  This is the last piece of the puzzle that is unique to Healixa, Inc. (OTC Pink: EMOR).

Marble Arch Research, Inc., on May 11th put a speculative buy rating on Healixa, Inc. with a target of $2.80 – $3.30 per share.  

Google Ads

With regard to sales, Marble Arch stated: “Healixa is starting to produce revenue through its digital pharmacy component which is expected to ramp quickly as it closes on additional pharmacy transactions. We project Healixa will report ~$130MN of revenues in FY 2022 (year ending March 31), its first full financial year as an operational virtual care company growing to ~$1BN in the next 5 years. Based on Healixa’s anticipated cost structure, the company looks well positioned to generate at least ~$8M of operating income in FY 2022, which we project will rise more than 20X to ~$180MN by FY 2026.”

Healixa is positioning itself as a next generation digital healthcare company with a more complete virtual care ecosystem than is currently available. 

The company is: 

         Embracing a broad range of specialties

         Expanding the scope of practice

         Integrating a digital pharmacy

         Obtaining national and potentially global distribution. 

Over the past year, Healixa Inc. (OTC Pink: EMOR) has cemented its status as an emerging market leader in healthtech.  Fueled by its recent fintech joint venture with Swys Inc., the name Healixa represents commitment to healing the fragmented user experience by blending the various elements of the digital assets.

Healixa is effectively developing a unique one-stop shop approach in the virtual care space. Moreover, its technology has the architecture to expand its suite of digital care solutions to include advanced patient monitoring, personalized medication instruction videos, and access to community resources, just to name those services that are currently being advanced in Healixa’s development pipeline.

Healixa has gone full circle with its marriage of health technology and financial technology and can be one of the biggest winners of the year.  

About EmergingGrowth.com

EmergingGrowth.com is a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies. Through its evolution, EmergingGrowth.com found a niche in identifying companies that can be overlooked by the markets due to, among other reasons, trading price or market capitalization. We look for strong management, innovation, strategy, execution, and the overall potential for long- term growth. Aside from being a trusted resource for the Emerging Growth info-seekers, we are well known for discovering undervalued companies and bringing them to the attention of the investment community. Through our parent Company, we also have the ability to facilitate road shows to present your products and services to the most influential investment banks in the space.

All information contained herein as well as on the EmergingGrowth.com website is obtained from sources believed to be reliable but not guaranteed to be accurate or all-inclusive. All material contained within this article was provided to EmergingGrowth.com by a third party, is for informational purposes only, is not the opinion of EmergingGrowth.com and should not be construed as an offer or solicitation to buy or sell securities. The information includes certain forward-looking statements, which may be affected by unforeseen circumstances and / or certain risks.  This report is not without bias. EmergingGrowth.com has motivation by means of either self-marketing or EmergingGrowth.com has been compensated by or for a company or companies discussed in this article. EmergingGrowth.com has been compensated three thousand seven hundred dollars in consideration for its work with Healixa, Inc., formerly Emerald Organic Products Inc. through the date this was published. EmergingGrowth.com may receive additional compensation and has received past compensation by or for this same company, details about which can be found in our full disclosure, here, https://emerginggrowth.com/6827465-3667/  You can easily loose money investing in highly speculative small cap stocks like the ones mentioned within. Please consult an investment professional before investing in anything viewed within. When EmergingGrowth.com is long shares it will sell those shares. In addition, please make sure you read and understand the Terms of Use, Privacy Policy and the Disclosure posted on the EmergingGrowth.com website.